Vimta Labs Ltd-$ — Q1 FY27 earnings call
Summary generated by AI from the official transcript Vimta Labs Ltd-$ filed with BSE on 24 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Vimta Labs reported Q1 FY27 total income of INR1,129 million, up 13.7% year-on-year, with EBITDA of INR411 million and PAT of INR210 million. Management said pharma contract research and testing grew year-on-year while food testing declined due to weaker import-export sample receipts linked to global trade challenges. The company secured and onboarded its first Biologics services order during the quarter and outlined an approximately INR80 crore capex plan for FY27.
2 statements from this call are not shown because their supporting quotes could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Total income: INR1,129 million (Q1 FY27)
p. 3
“Total income stood at INR1,129 million, representing year-on-year growth of 13.7%.”
Harita Vasireddi, page 3 of the filed PDF · View the filing
EBITDA: INR411 million (Q1 FY27)
p. 5
“EBITDA stood at INR411 million in Q1 FY27 as compared to INR354 million in Q1 FY26, up of 16% year-on-year.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
EBITDA margin: 36.4% (Q1 FY27)
p. 5
“EBITDA margins for the quarter stood at 36.4%.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
PAT: INR210 million (Q1 FY27)
p. 5
“PAT in Q1 '27 stood at INR210 million as compared to INR189 million in Q1 FY26, a growth of 11.4% year-on-year.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
PAT margin: 18.6% (Q1 FY27)
p. 5
“PAT margin for the quarter stood at 18.6%.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
Cash and cash equivalents: INR628.2 million (Q1 FY27)
p. 5
“we continue to have a net debt-free balance sheet with cash and cash equivalents of INR628.2 million.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
Customer retention rate: Upwards of 90%
p. 9
“Our retention rates are upwards of 90%.”
Harita Vasireddi, page 9 of the filed PDF · View the filing
Lab infrastructure occupancy: About 60% of 200,000 square feet
p. 10
“Infrastructure, see, we have built about 200,000 square feet. In that, I think we have occupied at least 60%, I would say, you know, approximately.”
Harita Vasireddi, page 10 of the filed PDF · View the filing
Biologics capex spent to date: Around INR20 crores of INR35 crores budget
p. 14
“We have spent around INR20 crores.”
Harita Vasireddi, page 14 of the filed PDF · View the filing
Electronics and Electrical testing capex: About INR40 crores
p. 14
“That is about INR40 crores-45 crores, I think. INR40 crores.”
Harita Vasireddi, page 14 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
FY27 capex — approximately INR80 crores · FY27
stated firmly by Siva Rama Krishna
p. 5
“We have slated a budget of approximately INR80 crores of capex spend for FY27 to primarily focus on strengthening our analytical capabilities and expanding select service offerings.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
Operating margins — coming quarters
stated conditionally by Harita Vasireddi
p. 7
“We expect that the margins will not go down further, because we are expecting the business to grow in the coming quarters.”
Harita Vasireddi, page 7 of the filed PDF · View the filing
Biologics contribution to top line and margin — from the third year onwards
stated as an aspiration by Harita Vasireddi
p. 12
“not this year, but hopefully, from the third year onwards, we expect it to be contributing significantly to the top line and margin.”
Harita Vasireddi, page 12 of the filed PDF · View the filing
Electronics and Electrical Testing state expansion — this year
stated firmly by Harita Vasireddi
p. 12
“There is no plan to expand into another state for this year.”
Harita Vasireddi, page 12 of the filed PDF · View the filing
Inorganic growth / acquisitions
stated as an aspiration by Harita Vasireddi
p. 14
“In theory, we think the company has reached a size where it can think of inorganic opportunities.”
Harita Vasireddi, page 14 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said growth momentum is being maintained barring Middle East-related global challenges, and clarified that utilization is not measured as a percentage.
Answered by Harita Vasireddi
Asked by Shubhi Gupta: Is the company on track for the INR500 crore revenue goal, and what is the current utilization level?
p. 5
“we are confident that the same momentum can be maintained in this year as well, barring the impact that the global challenges in the Middle East that everybody is facing.”
Harita Vasireddi, page 5 of the filed PDF · View the filing
Management declined to disclose customer details citing confidentiality agreements and said conversion timing of other prospects depends on project stage.
Answered by Harita Vasireddi
Asked by Krisha: Can management share details on the Biologics customer and order size, and the conversion timeline of other prospective clients?
p. 7
“Difficult to answer that question because the conversion depends on the stage at which their project is.”
Harita Vasireddi, page 7 of the filed PDF · View the filing
Management expects margins not to decline further as business grows in coming quarters.
Answered by Harita Vasireddi
Asked by Disha: Will operating margins decline further given facility expenses and raw material pressures?
p. 7
“We expect that the margins will not go down further, because we are expecting the business to grow in the coming quarters.”
Harita Vasireddi, page 7 of the filed PDF · View the filing
Management confirmed total commitments for the year will be INR80 crores including INR10 crores for biologics.
Answered by Siva Kambhampati
Asked by Yuvraj: What is the FY27 capex commitment breakdown versus the amount already spent in Q1?
p. 8
“our commitments for the current year will be INR80 crores, including the INR10 crores for biologics.”
Siva Kambhampati, page 8 of the filed PDF · View the filing
Management stated infrastructure was built with a roughly seven-year plan in mind, created two years ago, with about 60% of built space occupied.
Answered by Harita Vasireddi
Asked by Aditya Khaitan: What is the current capacity utilization of the laboratory infrastructure?
p. 10
“Infrastructure, see, we have built about 200,000 square feet. In that, I think we have occupied at least 60%, I would say, you know, approximately.”
Harita Vasireddi, page 10 of the filed PDF · View the filing
Management said pharma demand remains strong while food import-export activity has been impacted by geopolitical conflict.
Answered by Harita Vasireddi
Asked by Sai Surendra: Is demand from pharma or food testing still strong?
p. 10
“Pharma, strong. Food, the import and exports have been impacted because of the war situation, because the cost of import and export has gone up for the businesses.”
Harita Vasireddi, page 10 of the filed PDF · View the filing
Management cited a shift in Indian pharma pipelines toward complex and large molecules, and growth in domestic biotech companies, as favorable for CRO demand.
Answered by Harita Vasireddi
Asked by Vishal Manchanda: What tailwinds is management seeing in the pharma business?
p. 10
“The Indian pharmaceutical industry is moving away from simple small molecules. Their pipelines are now busy with more complex kind of molecules.”
Harita Vasireddi, page 10 of the filed PDF · View the filing
Management said about INR100 crores was spent creating 200,000 square feet of lab space, and fixed asset turns are expected to remain at similar average levels going forward.
Answered by Harita Vasireddi
Asked by Umesh Matkar: What has total capex been on facility expansion and Biologics, and will fixed asset turns improve?
p. 14
“We have spent close to INR100 crores on creating around 200,000 square feet of lab space in Genome Valley, Hyderabad.”
Harita Vasireddi, page 14 of the filed PDF · View the filing
Management confirmed some business was missed due to the Middle East issue but maintained the growth target is still on track.
Answered by Harita Vasireddi
Asked by Yogesh: How much revenue was missed in Q1 due to the Middle East crisis, and is the 20-25% full-year growth target still on track?
p. 16
“Yes, we missed, we missed some business because of the issue. We could have done much better had this issue not been out there.”
Harita Vasireddi, page 16 of the filed PDF · View the filing
Management said there is no active opportunity on the table currently.
Answered by Harita Vasireddi
Asked by Avneesh Burman: Is there an active acquisition or demerger opportunity under consideration?
p. 14
“No active opportunity on the table at the moment.”
Harita Vasireddi, page 14 of the filed PDF · View the filing
Risks flagged
Global challenges in the Middle East affecting business momentum
p. 5
“barring the impact that the global challenges in the Middle East that everybody is facing.”
Harita Vasireddi, page 5 of the filed PDF · View the filing
Decline in food testing import and export sample receipts due to global challenges
p. 4
“The food testing business witnessed a decline in import and export related sample receipts, primarily due to ongoing global challenges.”
Harita Vasireddi, page 4 of the filed PDF · View the filing
Margin pressure from facility-related expenses, new labor laws and rupee appreciation
p. 4
“operating margins moderated on a quarter-on-quarter basis, in line with expectations, largely due to higher facility-related expenses, the impact of new labor laws and appreciation of the rupee.”
Harita Vasireddi, page 4 of the filed PDF · View the filing
Rising cost of food import and export impacting trade due to war situation
p. 10
“Food, the import and exports have been impacted because of the war situation, because the cost of import and export has gone up for the businesses.”
Harita Vasireddi, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.